Company intelligence / Profile preview

Genetesis

Mason, Ohio, United Statesgenetesis.com ↗

Ownership: Private
Employees: ~26
Development stage: Commercial

Overview

Genetesis has developed and commercialized CardioFlux, a non-invasive medical imaging device that uses magnetocardiography to map the heart’s electrical currents. The technology aims to improve diagnosis of myocardial ischemia and coronary artery disease by providing more precise localization of abnormal cardiac activity compared to traditional ECG/EKG methods. Clinical adoption and results are ongoing as the company expands its footprint in healthcare settings.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-invasive cardiac imaging device
Industry: Medical Imaging

Drug pipeline

1 asset

CardioFlux

Commercial

Indications: Myocardial ischemia, Coronary microvascular dysfunction, Acute coronary syndrome

Partnerships

CincyTech (investor/partner)

Beyond the preview

Go deeper on Genetesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genetesis.

Explore the full profile